Allergy Therapeutics plc (LON:AGY) insider Peter Jensen bought 20,000 shares of the stock in a transaction that occurred on Tuesday, October 23rd. The stock was bought at an average price of GBX 18 ($0.24) per share, with a total value of £3,600 ($4,704.04).
AGY traded up GBX 0.12 ($0.00) during trading on Friday, hitting GBX 17.63 ($0.23). 375,522 shares of the company’s stock were exchanged, compared to its average volume of 167,682. Allergy Therapeutics plc has a 1 year low of GBX 23 ($0.30) and a 1 year high of GBX 39.50 ($0.52).
Several research firms have issued reports on AGY. Numis Securities reiterated a “buy” rating on shares of Allergy Therapeutics in a research note on Thursday, July 19th. FinnCap reiterated a “corporate” rating on shares of Allergy Therapeutics in a research note on Thursday, September 27th.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/2018/11/10/insider-buying-allergy-therapeutics-plc-agy-insider-purchases-3600-in-stock.html.
Allergy Therapeutics plc, a specialty pharmaceutical company, focuses on allergy vaccination primarily in Europe. The company's primary flagship product is the Pollinex Quattro for the treatment of allergic conditions. It offers monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen; sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; and synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen-Th, ATI Prob, and Pollagen.
Featured Story: What Does Beta Mean In Stock Selection
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.